Skip to main navigation
Tenaya Therapeutics
  • Careers at Tenaya
  • Contact Us
  • Leadership
  • Our Science
    • Platforms
    • Capabilities
    • Collaborations
    • Publications & Presentations
  • Our Programs
    • Pipeline
    • Programs
  • Patients & Families
    • Overview
    • Tenaya Approach
    • Advocacy Partners
    • Studies
    • Our Inspiration
    • Resources
  • Investors
    • News & Events
      • Press Releases
      • Events & Presentations
    • Corporate Governance
      • Governance Overview
      • Board of Directors
      • Management
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Quarterly Results
    • Stock Information
      • Stock Quote & Chart
    • IR Resources
      • Investor FAQs
      • Contact IR
      • Email Alerts

Investor Portal

May 10, 2023
Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023
Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting
May 02, 2023
Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201
Apr 21, 2023
Tenaya Therapeutics to Participate at Chardan's 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
Mar 08, 2023
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Feb 07, 2023
Tenaya Therapeutics to Participate in Upcoming Investor Conferences
Jan 09, 2023
Tenaya Therapeutics Announces TN-201 IND Clearance and Anticipated 2023 Milestones
RSS Feeds
Email Alerts
Contact IR
Print

Privacy Policy | Terms of Use    © 2023 Tenaya Therapeutics. All rights reserved.